Portugal is not an obvious destination for international venture capital funding, but that might be part of its new-found attraction. The EU country has just attracted the first international life sciences specialist VC firm, Vesalius Biocapital, to invest in its life sciences and healthcare sectors, and other VCs may soon follow that lead.
Portugal: An Uptick In Life Science VC Funding
An international VC, Vesalius Biocapital, is to invest in start-up life sciences and biotech companies in the western European country that is developing an entrepreneurial ecosystem.
More from Financing
• By
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
• By
Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.
• By
Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.
• By
The Swiss biotech firm could go public on the NASDAQ later this year, and points to other preclinical dealmaking in the space to back its strategy.
More from Business
• By
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.
• By
CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.